JP
PBYI icon

Jana Partners’s Puma Biotechnology PBYI Stock Holding History

Jana Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-142,727
Closed -$4.38M – 60
2016
Q4 		$4.38M Buy
142,727
+66,653
+88% +$2.88M 0.08% 45
2016
Q3 		$5.1M Buy
+76,074
New +$3.85M 0.09% 39

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jana Partners's PBYI Position: Q1 2017 in Review

Jana Partners sold out of Puma Biotechnology (PBYI) in Q1 2017, closing a stake of 142,727 shares — an estimated $4.38M sold.

Jana Partners first reported a position in PBYI in Q3 2016 and held it in 2 quarters. The position peaked at $5.1M in Q3 2016. 136 funds tracked by Wall St. Rank hold PBYI as of Q1 2017.

  • Jana Partners reported no remaining Puma Biotechnology position as of Q1 2017 after selling out during the quarter.
  • Jana Partners sold 142,727 Puma Biotechnology shares in Q1 2017, an estimated $4.38M.
  • Jana Partners first reported a position in Puma Biotechnology in Q3 2016 and held it in 2 quarters.
  • Jana Partners's Puma Biotechnology position peaked at $5.1M in Q3 2016.
  • 136 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2017.

Based on Jana Partners's 13F filing for Q1 2017, filed 15 May 2017.